Neovascular-targeted immunoconjugates

Details Neovascular-targeted immunoconjugates Neovascular-targeted immunoconjugates

2005-05-23

2010-12-28

Rawlings, Stephen L (Department: 1643)

Drug, bio-affecting and body treating compositions

Conjugate or complex of monoclonal or polyclonal antibody,...

Conjugate includes potentiator; or composition comprising...

C424S178100, C514S002600, C530S384000, C530S387100, C530S387300, C530S391700

Reexamination Certificate

active

07858092

ABSTRACT:
Immunoconjugates for treating diseases associated with neovascularization such as cancer, rheumatoid arthritis, the exudative form of macular degeneration, and atherosclerosis are described. The immunoconjugates typically consist of the Fc region of a human IgG1 immunoglobulin including the hinge, or other effector domain or domains that can elicit, when administered to a patient, a cytolytic immune response or cytotoxic effect against a targeted cell. The effector domain is conjugated to a targeting domain which comprises a factor VII mutant that binds with high affinity and specificity to tissue factor but does not initiate blood clotting such as factor VII having a substitution of alanine for lysine-341 or of alanine for serine-344.

REFERENCES:
patent: 4752569 (1988-06-01), Terasaki et al.
patent: 4784950 (1988-11-01), Hagen et al.
patent: 4865998 (1989-09-01), Feickert et al.
patent: 4959318 (1990-09-01), Foster et al.
patent: 4997762 (1991-03-01), Hanna, Jr. et al.
patent: 5091513 (1992-02-01), Huston et al.
patent: 5098833 (1992-03-01), Lasky et al.
patent: 5116964 (1992-05-01), Capon et al.
patent: 5216131 (1993-06-01), Lasky et al.
patent: 5225538 (1993-07-01), Capon et al.
patent: 5288629 (1994-02-01), Berkner
patent: 5428130 (1995-06-01), Capon
patent: 5455165 (1995-10-01), Capon et al.
patent: 5514582 (1996-05-01), Capon et al.
patent: 5516650 (1996-05-01), Foster et al.
patent: 5541087 (1996-07-01), Lo et al.
patent: 5605690 (1997-02-01), Jacobs et al.
patent: 5714147 (1998-02-01), Capon et al.
patent: 5759808 (1998-06-01), Casterman et al.
patent: 5788965 (1998-08-01), Berkner et al.
patent: 5800988 (1998-09-01), Casterman et al.
patent: 5817788 (1998-10-01), Berkner et al.
patent: 5824639 (1998-10-01), Berkner
patent: 5833982 (1998-11-01), Berkner et al.
patent: 5840526 (1998-11-01), Casterman et al.
patent: 5840844 (1998-11-01), Lasky et al.
patent: 5861374 (1999-01-01), Berkner et al.
patent: 5877289 (1999-03-01), Thorpe et al.
patent: 5879672 (1999-03-01), Davis et al.
patent: 5939530 (1999-08-01), Gelboin et al.
patent: 5969107 (1999-10-01), Carceller et al.
patent: 5981471 (1999-11-01), Papathanassiu et al.
patent: 6001978 (1999-12-01), Edgington et al.
patent: 6005079 (1999-12-01), Casterman et al.
patent: 6015695 (2000-01-01), Casterman et al.
patent: 6017514 (2000-01-01), Epstein et al.
patent: 6039944 (2000-03-01), Berkner et al.
patent: 6132729 (2000-10-01), Thorpe et al.
patent: 6140470 (2000-10-01), Garen et al.
patent: 6342219 (2002-01-01), Thorpe et al.
patent: 6406697 (2002-06-01), Capon et al.
patent: 6448071 (2002-09-01), Schneck et al.
patent: 6479729 (2002-11-01), Campochiaro et al.
patent: 6541610 (2003-04-01), Smith
patent: 6555319 (2003-04-01), Wong et al.
patent: 6572852 (2003-06-01), Smith et al.
patent: WO 90/14430 (1990-11-01), None
patent: WO-93/17715 (1993-09-01), None
patent: WO 94/26787 (1994-11-01), None
patent: WO-96/01653 (1996-01-01), None
patent: WO-98/31394 (1998-07-01), None
Mori et al Investigative Ophthalmology and Visual Science, 43(7):2428-2434, Jul. 2002.
Tosatto et al Current Pharmaceutical Design, 12(17):2067-2086, 2006.
Dennis Nature, 442:739-741, Aug. 2006.
Srivastava Nature Immunology, 1(5):363-366, Nov. 2000.
Tarnawski Digestive Diseases and Sciences, 50:S24-S33, Oct. 2005.
Kijlstra et al Ocular Immunology and Inflammation, 13:3-11, 2005.
Kelland European Journal of Cancer, 40:827-836, 2004.
Schwesinger et al American Journal of Pathology, 158(3):1161-1172, Mar. 2001.
Roodhooft Bulletin De La Socitie Belge D'Ophtalmologie, 276, 83-92, 2000.
Grossniklaus et al Molecular Vision, 8:19-126, Apr. 2002.
Kimizuru et al Investigative Ophthalmology and Visual Science, 42(11):2664:2672, Oct. 2001.
Kipps et al. (J. Exp. Med., 161(1):1-17, 1985).
Lebherz et al (Diabetes, 54:1141-1149, Apr. 2005).
Vinores et al. (Adv. Exp. Med. Biol. 2000; 476: 129-138).
McVey et al (Blood, 92(3):920-926, 1998).
Schuh (Toxicologic Pathology. 2004; 32 (Suppl. 1): 53-66).
Gura (Science. 1997; 278: 1041-1042).
Hermann et al (Sem. Thr. Mem., 26(4):393-40, 2000).
Umeda et al (FASEB, 19:1683-1685, 2005).
Nakagaki et al. Biochemistry, 30(45):10819-10824, 1991.
Olson et al. International Journal of Cancer, 73:865-870, 1997.
Drake et al. American Journal of Pathobiology, 134(5):1087-1097, 1989.
Contrino et al. Nature Medicine, 2:209-215, 1996.
Min et al. Cancer Research, 56:2428-2432, 1996.
Cruse et al. Illustrated Dictionary of Immunology, CRC Press, p. 109, 1995.
Rudifoff et al. Proc. Natl. Acad. Sci. USA, 79:1979-1983, 1982.
Lederman et al. Molecular Immunology 28:1171-1181, 1991.
Li et al. Proc. Natl. Acad. Sci. USA 77:3211-3214, 1980.
Coleman P. M. Research in Immunology, 145:33-36, 1994.
Hu, Z., et al., Proc. Natl. Acad. Sci. USA 96: 8161-8166 (1999).
Hu, Z., and Garen, A., Proc. Natl. Acad. Sci. USA 98: 12180-12185 (2001).
Huang, X., et al., Science 275: 547-550 (1997).
Wang, B., et al., Proc. Natl. Acad. Sci. USA 96: 1627-1632 (1999).
Ruoslahti, E., Nature Reviews 2: 83-90 (2002).
Gewolb, J. “New Cancer Therapy Kills Blood Vessels,”Science On Line, Oct. 1, 2001.
“Molecule May Kill Cancer Tumors,”The Associated Press, Oct. 1, 2001.
Schubert, Charlotte. “Meddling in macular degeneration,”Nature Medicine, Apr. 2003. vol. 9, No. 4, p. 396.
Kimura et al., “The Potential of Active Drug Targeting with Immunoconjugates to Choroidal Neovescularization”, IOVS, vol. 41, No. 4, Mar. 15, 2000, p. S180.
Dal Porto et al., “A soluble divalent class I major hisocompatibility compelx molecule inhibits alloreactive T cells at nanomolar concentrations”,Proc. Natl., Acad. Sci USA, Jul. 1993, pp. 6671-6675, vol. 90.
Eilat et al., “Secretion of a soluble, chimeric γ{hacek over (o)} T-cell receptor-immunoglobulin heterodimer”,Proc. Natl. Acad. Sci. USA, Aug. 1992. pp. 6871-6875, vol. 89.
Grégoire et al., “Engineered secreted T-cell receptor αβ heterodimers”,Proc. Natl. Acad. Sci. USA, Sep. 1991, pp. 8077-8081, vol. 88.
Mohler et al., “Soluble Tumor Necrosis Factor (TNF) Receptors Are Effective Therapeutic Agents in Lethal Endotoxemia and Function Simultaneously as Both TNF Carriers and TNF Antagonists”,J. Immunol., Aug. 1993, pp. 1548-1561, vol. 151. No. 3.
Erben et al., “Differential effects of a stem cell factor-immunoglobulin fusion protein on malignant and normal hematopoietic cells”,Cancer Res., Jun. 1999, pp. 2924-2930, vol. 59, No. 12 (Abstract only).
Baba, E., “Effects of IgC-Fc-mitomycin C conjugate on cancer cells”,Hokkaido Igaku Zasshi, Mar. 1996, pp. 271-281, vol. 71, No. 2 (Article in Japanese; abstract only).
Peppel et al., “A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity”,J. Exp. Med., Dec. 1991, pp. 1483-1489, vol. 174, No. 6. (Abstract only).
E. Wilmes et al., “Versuche zur Herstellung menschlicher monoklonaler Antikorper gegen Melanome unter Verwendung zervikaler Lymphknoten,”Laryng. Rhinol. Otol., (1987), vol. 66, pp. 144-148.
Jamie K. Scott and George Smith, “Searching for Peptide Ligands with an Epitope Library,”Science, (Jul. 27, 1990), vol. 249, pp. 386-390.
James D. Marks et al., “By-passing Immunization Human Antibodies from V-gene Libraries Displayed on Phage,”J. Med Biol., (1991), vol. 222, pp. 581-597.
Greg Winter and Cesar Milstein, “Man-made Antibodies,”Nature, (Jan. 24, 1991), vol. 349, pp. 293-299.
James D. Marks et al., By-passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling,Bio/Technology, (Jul. 1992), vol. 10, pp. 779-783.
G. Del Bino et al., “Apoptotic Cell Death Triggered by Camptothacin or Tenipos.de. The Cell Cycle Specificity and Effects of Ionizing Radiation,”Cell Prolif., (1992), vol. 25, pp. 537-548.
Andrew D. Griffiths et al., “Human Anti-self Antibodies with High Specificity from Phage Display Libraries,”The EMBO Journal, (1993), vol. 12, No. 2, pp. 725-734.
Lee H. Pai and Ira

Affiliated with

Also associated with

Rating

Neovascular-targeted immunoconjugates does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Neovascular-targeted immunoconjugates, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Neovascular-targeted immunoconjugates will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4191398